Formulation, Optimization and Evaluation of In-Situ Nasal Gel Loaded with Clonazepam Liposomes

Abstract

Intranasal administration provides a promising alternative to oral and injectable methods, especially for targeting the central nervous system (CNS). Clonazepam, a benzodiazepine used for treating epilepsy and anxiety, has low oral bioavailability due to its poor water solubility and extensive first-pass metabolism. A liposomal in-situ nasal gel formulation was created to improve brain targeting and sustain drug release, addressing this issue. Liposomes containing clonazepam were created using the thin-film hydration technique and optimized through Central Composite Design (CCD), adjusting the amounts of soya lecithin and cholesterol. Key responses included entrapment efficiency (%EE) and drug release at 8 hours (%DR). Using Poloxamer 407 and Carbopol 934, the optimized liposomes were integrated into a thermo- and pH-responsive in-situ gel, which was further fine-tuned for drug content and release. The characteristics of the formulation were determined for size, zeta potential, FTIR, TEM, viscosity, muco-adhesion, and in vitro diffusion. The liposomal batch (L5) that was optimized exhibited an EE of 79.80% and a drug release of 73.72% over the course of 8 hours. The vesicles measured approximately 380 nm and had a zeta potential of -46.35 mV, which suggests stability. The drug release adhered to a zero-order kinetic model and exhibited Super Case-II transport characteristics. The final gel (L5G4) demonstrated a drug content of 71.68% and a release rate of 83.09%, gelling at approximately 33°C while exhibiting optimal viscosity and mucoadhesive characteristics. Reliability of the formulation was confirmed through statistical validation. The produced liposomal in-situ gel boosts intranasal delivery of Clonazepam, providing sustained release, better brain targeting, and potential for greater patient adherence compared to traditional forms.

Keywords

• Clonazepam
• Liposomes
• Nasal drug delivery system
• Central Composite Design
• In-Situ Gel.

References

1. [1] Anjali S, Abhijeet K, Ajay S, Kulkarni A. Nasal in situ gel: novel approach for nasal drug delivery. J Drug Deliv Ther. 2020;10:183-97. http://dx.doi.org/10.22270/jddt.v10i2-s.4029
2. [2] Mujawar N, Ghatage S, Navale S, Sankpal B, Patil S, Patil S. Nasal drug delivery: Problem solution and its application. Journal of Current Pharma Research. 2014 Apr 1;4(3):1231.
3. [3] Stock AD, Gelb S, Pasternak O, Ben-Zvi A, Putterman C. The blood brain barrier and neuropsychiatric lupus: new perspectives in light of advances in understanding the neuroimmune interface. Autoimmunity reviews. 2017 Jun 1;16(6):612-9. https://doi:10.1016/j.autrev.2017.04.008
4. [4] Pires PC, Santos AO. Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies. Journal of controlled release. 2018 Jan 28;270:89-100 https://doi.org/10.1016/j.jconrel.2017.11.047
5. [5] Kulkarni AD, Vanjari YH, Sancheti KH, Belgamwar VS, Surana SJ, Pardeshi CV. Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review. Journal of drug targeting. 2015 Oct 21;23(9):775-88. https://doi.org/10.3109/1061186X.2015.1020809
6. [6] Mara Mainardes R, Cristina Cocenza Urban M, Oliveira Cinto P, Vinicius Chaud M, Cesar Evangelista R, Palmira Daflon Gremiao M. Liposomes and micro/nanoparticles as colloidal carriers for nasal drug delivery. Current Drug Delivery. 2006 Jul 1;3(3):275-85. https://doi.org/10.2174/156720106777731019
7. [7] Sharma Vijay K, Mishra D, Sharma A, Srivastava B. Liposomes: present prospective and future challenges. International journal of current pharmaceutical review & research. 2010 Aug;1(2):6-16.
8. [8] Robinson JR, Mlynek GM. Bioadhesive and phase-change polymers for ocular drug delivery. Advanced Drug Delivery Reviews. 1995 Aug 1;16(1):45-50. https://doi.org/10.1016/0169-409X(95)00013-W

9. [9] Krauland AH, Leitner VM, Bernkop‐Schnürch A. Improvement in the in situ gelling properties of deacetylated gellan gum by the immobilization of thiol groups. Journal of pharmaceutical sciences. 2003 Jun;92(6):1234-41.https://doi.org/10.1002/jps.10371
10. [10] Mahajan HS, Gattani S. In situ gels of metoclopramide hydrochloride for intranasal delivery: in vitro evaluation and in vivo pharmacokinetic study in rabbits. Drug delivery. 2010 Jan 1;17(1):19-27. https://doi.org/10.3109/10717540903447194
11. [11] Tatode AA, Patil AT, Umekar MJ. Application of response surface methodology in optimization of paclitaxel liposomes prepared by thin film hydration technique. Int J Appl Pharm. 2018 Mar; 10:62-9. http://dx.doi.org/10.22159/ijap.2018v10i2.24238
12. [12] Jain A, Hurkat P, Jain SK. Development of liposomes using formulation by design: Basics to recent advances. Chemistry and physics of lipids. 2019 Nov 1; 224:104764. https://doi.org/10.1016/j.chemphyslip.2019.03.017
13. [13] Ramya K., Devi Seetha A. Formulation and evaluation of valacyclovir liposomes. International Journal Pharmaceutical Sciences and Research 2021; 12:5: 2913-2919.
14. [14] Singh R., Dharma H., Choubey N., Tyagi C., Budholiya P., Parkhe G., Formulation and evaluation of liposomal gel for effective treatment of acne. Asian Journal of Pharmaceutical education and research 2019; 8: 3: 64-7
15. [15] A. Bilapatte, A. More, K. Satpute, S.M. Syed, Formulation and evaluation of carbamazepine loaded ethosomal nasal in-situ gel for brain targeted drug delivery, Journal of Holistic Integrative Pharmacy, 6 (2025) 57-63. https://doi.org/10.1016/j.jhip.2025.03.002
16. [16] Rajesh S, Mohiddin SK, Syed S, Abhivardhan R, Gowtham M, Hemanth N, Akhil PS. Enhancing permeability of acyclovir by liposomal drug delivery system. Indo American Journal of Pharmaceutical Research 2023.:754-762 http://doi.org/10.5281/zenodo.7847954
17. [17] Patel RP, Patel H, Baria A. Formulation and evaluation. Int J Drug Deliv Technol. 2009; 1:42-5.
18. [18] Brahmankar DM, Jaiswal SB. Biopharmaceutics and pharmacokinetics-a treatise Vallabh Prakashan. New Delhi. 1995.
19. [19] Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, Xie S. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. The AAPS journal. 2010 Sep; 12:263-71. https://doi.org/10.1208/s12248-010-9185-1
20. [20] Shivsharan US, Hosmani AH, Thorat YS. Optimization of Thermo-reversible Nasal Gel of Carbamazepine for Better Control in Chronic Epilepsy. In Techno-Societal 2016, International Conference on Advanced Technologies for Societal Applications 2022 Dec 9 (pp. 487-494). Cham: Springer International Publishing https://doi.org/10.1007/978-3-031-34648-4_48
21. [21] Duong VA, Nguyen TT, Maeng HJ. Recent advances in intranasal liposomes for drug, gene, and vaccine delivery. Pharmaceutics. 2023 Jan 6; 15(1):207. https://doi.org/10.3390/pharmaceutics15010207
22. [22] Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102. https://doi.org/10.1186/1556-276X-8-102
23. [23] Marttin E, Schipper NG, Verhoef JC, Merkus FW. Nasal mucociliary clearance as a factor in nasal drug delivery. Advanced drug delivery reviews. 1998 Jan 5;29(1-2):13-38. https://doi.org/10.1016/S0169-409X(97)00059-8
24. [24] Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Advanced drug delivery reviews. 2005 Nov 3;57(11):1640-65. https://doi.org/10.1016/j.addr.2005.07.009
25. [25] Jiang L, Gao L, Wang X, Tang L, Ma J. The application of mucoadhesive polymers in nasal drug delivery. Drug development and industrial pharmacy. 2010 Mar 1;36(3):323-36. https://doi.org/10.3109/03639040903170750
26. [26] Callens C, Remon JP. Evaluation of starch–maltodextrin–Carbopol® 974 P mixtures for the nasal delivery of insulin in rabbits. Journal of controlled release. 2000 May 15;66(2-3):215-20. https://doi.org/10.1016/S0168-3659(99)00271-0
27. [27] Mura P, Mennini N, Nativi C, Richichi B. In-situ mucoadhesive-thermosensitive liposomal gel as a novel vehicle for nasal extended delivery of opiorphin. European Journal of Pharmaceutics and Biopharmaceutics. 2018 Jan 1;122:54-61. https://doi.org/10.1016/j.ejpb.2017.10.008
28. [28] A. Nidbane, A. Dound, K. Satpute, S.M. Syed, Development of a novel luliconazole transferosomal gel for enhanced antifungal delivery, Journal of Dermatologic Science and Cosmetic Technology, 2 (2025) 100071. https://doi.org/10.1016/j.jdsct.2025.100071